Gene Expression Profiling of HR Repair Pathways Predicts PARP Inhibitor Response in Malignant Pleural Mesothelioma

Study Background and Research Question

Malignant pleural mesothelioma (MPM) is a devastating malignancy originating from the mesothelial lining of the pleural cavities. Despite the availability of combination chemotherapies—most notably cisplatin with pemetrexed disodium—patient outcomes remain suboptimal, with median survival rarely exceeding 12 months. A persistent challenge in cancer chemotherapy research for MPM is the high rate of chemoresistance and disease recurrence. The biological underpinnings of this resistance have been incompletely understood, but recent attention has focused on the DNA damage response, particularly defects in the homologous recombination repair (HRR) pathway—a collection of genetic alterations collectively referred to as “BRCAness.”

Borchert et al. (2019) addressed a key question: can profiling HRR gene expression identify MPM subtypes with increased susceptibility to poly(ADP-ribose) polymerase (PARP) inhibition, and do these molecular signatures offer a path to more personalized, effective therapies? (reference study).

Key Innovation from the Reference Study

The central innovation of Borchert et al.'s work lies in the integration of comprehensive gene expression profiling for HRR pathway components to stratify MPM tumors. Rather than relying solely on the presence of BRCA1/2 mutations, the study expands the concept of BRCAness to include a broader spectrum of HRR defects, notably mutations in the BRCA-associated protein 1 (BAP1) gene. This expanded profiling enables identification of tumors dependent on alternative DNA repair mechanisms, such as PARP1-mediated base excision repair, thus revealing new therapeutic vulnerabilities.

Another key advance is the demonstration that PARP inhibition, particularly with olaparib, induces apoptosis and senescence selectively in MPM cell lines harboring BRCAness features, especially BAP1 loss. This finding provides a mechanistic rationale for exploring PARP inhibitors in MPM beyond the traditional BRCA-mutant paradigm.

Methods and Experimental Design Insights

The study employed a combined approach of in vitro drug sensitivity assays and digital gene expression profiling:

• Three MPM cell lines (including BAP1-mutant NCI-H2452) and control lung fibroblasts were exposed to single-agent and combined regimens of pemetrexed, cisplatin, and olaparib.
• Apoptosis and senescence induction were quantified following treatment, with particular attention to the effect of combining DNA-damaging agents with PARP inhibition.
• Beyond cell models, the authors digitally screened 91 clinical MPM samples for expression levels of 91 genes related to HRR, identifying patterns associated with the BRCAness phenotype.
• Gene expression data were correlated with clinical outcomes and assessed for the potential to stratify patients by likely therapeutic response.

Core Findings and Why They Matter

The reference study yielded several impactful findings:

• BRCAness Prevalence: Defects in HRR, encompassing but not limited to BRCA1/2 and BAP1, were common in MPM samples. The BAP1 mutation alone was present in up to 64% of cases, aligning with previous reports (Borchert et al., 2019).
• Therapeutic Susceptibility: MPM cell lines with BRCAness features—especially BAP1 mutations—exhibited increased apoptosis and senescence upon PARP inhibition with olaparib. Synergistic effects were observed when olaparib was combined with cisplatin, suggesting that dual targeting of DNA repair and DNA damage pathways could overcome resistance mechanisms in a significant subset (potentially up to two-thirds) of MPM patients.
• Biomarker Identification: The expression levels of specific HRR-related genes, including Aurora Kinase A (AURKA), RAD50, and DNA damage-binding protein 2 (DDB2), emerged as prognostic markers for MPM, offering avenues for future biomarker-driven treatment strategies.
• Clinical Relevance: Approximately 10% of clinical samples displayed the BRCAness-associated gene expression pattern, indicating a non-trivial proportion of MPM patients who may benefit from stratified chemotherapeutic interventions.

Collectively, these findings suggest that gene expression profiling of HRR components can be leveraged to identify MPM patients most likely to respond to PARP inhibitors, thus refining current therapeutic paradigms and informing ongoing clinical trial design.

Comparison with Existing Internal Articles

Several recent reviews and laboratory guidance resources expand on the mechanistic and translational context of pemetrexed-based therapies:

• The article "Pemetrexed as a Multi-Targeted Antifolate" details the compound’s role as a TS, DHFR, and GARFT inhibitor, emphasizing its disruption of nucleotide biosynthesis and relevance to overcoming chemoresistance. These mechanisms are highly pertinent to the DNA repair vulnerabilities highlighted by Borchert et al., linking antifolate action to increased DNA damage and potential synergy with PARP inhibitors.
• "Gene Expression Profiling Predicts PARP Inhibitor Response in MPM" provides an accessible summary of Borchert et al.'s findings, reinforcing the translational potential of HRR profiling for biomarker-driven therapy stratification.
• In "Pemetrexed (LY-231514): Multi-Targeted Antifolate for Cancer Research", the focus is on pemetrexed’s application in advanced cell models, supporting the combination strategies used in the reference study’s in vitro experiments.

Together, these resources underscore the value of integrating targeted antifolate agents with DNA repair pathway inhibitors—an approach directly supported by the mechanistic findings of Borchert et al.

Protocol Parameters

• Pemetrexed dosing: In vitro studies have used concentrations ranging from 0.0001 to 30 μM over 72 hours for assessing antiproliferative activity in human tumor cell lines, as reported in the product information.
• Combination therapy: For synergy studies, sequential or concurrent treatment of MPM cell lines with cisplatin, pemetrexed, and PARP inhibitors (e.g., olaparib) can be modeled; Borchert et al. applied these regimens to assess apoptosis and senescence endpoints.
• Gene expression screening: Digital profiling can be performed on clinical samples or cell lines to assess HRR component expression, aiding in stratification and biomarker discovery.
• Cell line selection: Use of BAP1-mutant and HRR-defective MPM cell lines is recommended for studying BRCAness and PARP inhibitor responses.

Limitations and Transferability

While the study by Borchert et al. offers compelling evidence for the role of HRR profiling in guiding PARP inhibitor therapy, several limitations must be considered:

• All functional validation was performed in vitro; the extent to which these findings translate to in vivo models and clinical settings requires further exploration.
• The prevalence of actionable BRCAness signatures was approximately 10% in patient samples, suggesting that broader utility will depend on improved detection and stratification methods.
• Combination treatment regimens may introduce additional toxicity, highlighting the importance of careful dose optimization and workflow validation in preclinical studies.

Despite these caveats, the approach detailed in the reference study provides a framework for rational development of stratified therapies in MPM and potentially other difficult-to-treat cancers.

Research Support Resources

To facilitate laboratory research on DNA repair vulnerabilities and combination chemotherapy strategies, researchers may utilize reagents such as Pemetrexed (SKU A4390) from APExBIO. This compound is a well-characterized antifolate antimetabolite, enabling reproducible modeling of nucleotide biosynthesis inhibition and chemoresistance in tumor cell lines. Protocols using pemetrexed can be adapted to study synergistic effects with DNA repair pathway inhibitors, aligning with the workflow demonstrated in Borchert et al. (2019).

For more detailed guidance on optimizing pemetrexed-based assays and integrating gene expression profiling, refer to scenario-driven laboratory articles and advanced protocol recommendations linked above.